Evidence map›Paper›PMID 31175983›Full record

ArticleFree radical biology & medicine2019

Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Richard A Maki, Michael Holzer, Khatereh Motamedchaboki, Ernst Malle, Eliezer Masliah, Gunther Marsche, Wanda F Reynolds

Open access · greenAbstract read
In one paragraph

Article in Free radical biology & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 59 citations in OpenAlex.

  1. Designing lysate-based hydrogels for on-demand therapy.Journal of pharmaceutical analysis · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Positron Emission Tomography with [International journal of molecular sciences · 2024
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. MPO/HOCl Facilitates Apoptosis and Ferroptosis in the SOD1Oxidative medicine and cellular longevity · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Richard A MakiSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Michael HolzerOtto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Austria.
Khatereh MotamedchabokiTumor Initiation & Maintenance Program and NCI Cancer Centre Proteomics Facility, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Ernst MalleGottfried Schatz Research Center, Division of Molecular Biology and Biochemistry, Medical University of Graz, Austria.
Eliezer MasliahMolecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA; Department Neurosciences, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA; Department of Pathology, School of Medicine, University of California, San Diego, La Jolla, CA, 92093, USA.
Gunther MarscheOtto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Austria.
Wanda F ReynoldsSanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. Electronic address: wreynolds@sbpdiscovery.org.
Discovery Institute · USMedical University of Graz · ATNational Institutes of Health · US

Funding

Neuroimmune responses and therapeutics of alpha-synucleinopathies of the aging populationZIAAG000936 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2017 to 2025
$4.1M
MPO oxidants in synucleinopathiesR01NS074303 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI REYNOLDS, WANDA F · 2011 to 2015
$1.9M
MYELOPEROXIDASE INVOLVEMENT IN ALZHEIMER'S DISEASER01AG017879 · NIA · SIDNEY KIMMEL CANCER CENTER · PI REYNOLDS, WANDA F · 2001 to 2005
$1.9M
Intramural NIH HHS Z99 AG999999Intramural NIH HHS ZIA AG000936NIA NIH HHS R01 AG017879NINDS NIH HHS R01 NS074303
6 · The paper itself

Abstract

α-Synuclein (αSyn) is central to the neuropathology of Parkinson's disease (PD) due to its propensity for misfolding and aggregation into neurotoxic oligomers. Nitration/oxidation of αSyn leads to dityrosine crosslinking and aggregation. Myeloperoxidase (MPO) is an oxidant-generating enzyme implicated in neurodegenerative diseases. In the present work we have examined the impact of MPO in PD through analysis of postmortem PD brain and in a novel animal model in which we crossed a transgenic mouse expressing the human MPO (hMPO) gene to a mouse expressing human αSyn-A53T mutant (A53T) (hMPO-A53T). Surprisingly, our results show that in PD substantia nigra, the hMPO gene is expressed in neurons containing aggregates of nitrated αSyn as well as MPO-generated HOCl-modified epitopes. In our hMPO-A53T mouse model, we also saw hMPO expression in neurons but not mouse MPO. In the mouse model, hMPO was expressed in neurons colocalizing with nitrated αSyn, carbamylated lysine, nitrotyrosine, as well as HOCl-modified epitopes/proteins. RNAscope in situ hybridization confirmed hMPO mRNA expression in neurons. Interestingly, the hMPO protein expressed in hMPO-A53T brain is primarily the precursor proMPO, which enters the secretory pathway potentially resulting in interneuronal transmission of MPO and oxidative species. Importantly, the hMPO-A53T mouse model, when compared to the A53T model, exhibited significant exacerbation of motor impairment on rotating rods, balance beams, and wire hang tests. Further, hMPO expression in the A53T model resulted in earlier onset of end stage paralysis. Interestingly, there was a high concentration of αSyn aggregates in the stratum lacunosum moleculare of hippocampal CA2 region, which has been associated in humans with accumulation of αSyn pathology and neural atrophy in dementia with Lewy bodies. This accumulation of αSyn aggregates in CA2 was associated with markers of endoplasmic reticulum (ER) stress and the unfolded protein response with expression of activating transcription factor 4 (ATF4), C/EBP homologous protein (CHOP), MPO, and cleaved caspase-3. Together these findings suggest that MPO plays an important role in nitrative and oxidative damage that contributes to αSyn pathology in synucleinopathies.

Indexed as

Disease Models, AnimalAnimalsCarbonEpitopesFemaleHumansMaleMaze LearningMiceMice, TransgenicMotor DisordersMotor SkillsNeuronsNitrogenOxidative StressParkinson DiseaseCarbonEpitopesMPO protein, humanNitrogenPeroxidaseAlpha synucleinCarbamylationDementia with lewy bodiesER stressHippocampus CA2 regionHypochlorous acidMPO-H(2)O(2)-chloride systemMyeloperoxidaseNitrationParkinson's diseaseReactive oxygen speciesSynucleinopathiesUnfolded protein response

Identifiers

PMID31175983
PMCPMC6774439
OpenAlexW2948686984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.